JNJ
Johnson & JohnsonNYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
21.85
PEG
0.24
P/B
7.24
P/S
6.22
EV/EBITDA
15.41
DCF Value
$316.55
FCF Yield
3.4%
Div Yield
2.1%
Margins & Returns
Gross Margin
72.8%
Operating Margin
27.2%
Net Margin
28.5%
ROE
33.8%
ROA
26.8%
ROIC
13.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $24.56B | $5.12B | $2.10 |
| FY 2025 | $94.19B | $26.80B | $11.03 |
| Q3 2025 | $23.99B | $5.15B | $2.12 |
| Q2 2025 | $23.74B | $5.54B | $2.29 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NYSE
Beta
0.33
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.